NewsRoom Articles

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

WednesdayApr 15, 2026 11:15 am

Frontieras North America Inc. Launches New Era for Full Coal Utilization

Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal. The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing. At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components. Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed…

WednesdayApr 15, 2026 10:00 am

Scientists Discover Brain Cells That Aid Brain Cancer Development

Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive support structures in healthy brain tissue have been found to actively fuel tumor growth through signaling that boosts cancer cell function. The discovery also points toward a drug already in wide clinical use that may be capable of interrupting that process. Both findings represent meaningful advances in a field that has seen very limited therapeutic progress over several decades. Glioblastoma carries one of oncology's bleakest prognoses, with survival following diagnosis typically measured in months rather than years. Patients have access to very few effective treatment…

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

MondayApr 13, 2026 10:00 am

New Urine Test Boosts Forecasting of Treatment Outcomes in Bladder Cancer

Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already cured by surgical removal, transforming treatment planning for roughly 60,000 Americans diagnosed yearly with early-stage disease. The screening can detect cancer recurrence months ahead of visible tumor growth, enabling physicians to strengthen interventions for vulnerable patients while avoiding unnecessary treatment for others already disease-free. Early-stage bladder cancer returns frequently despite prompt intervention. Following tumor removal, patients showing high-risk characteristics undergo six weekly BCG immunotherapy bladder treatments aimed at preventing disease comeback. Surgery alone cures some individuals while others experience cancer…

MondayApr 13, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Targets Growing Billion-Dollar Train Safety Market with AI Obstacle Detection Systems

The global train collision avoidance system market is expected to reach $13.32 billion by 2030, growing at a compound annual growth rate (“CAGR”) of an estimated 15%. Rail Vision’s offerings have been described as AI-powered perception systems that allow rail operators to predict and prevent collisions. The company's two flagship products serve different operational environments but share the same underlying technological architecture. The global train collision avoidance market is undergoing a dramatic transformation, driven by the convergence of advanced camera systems and artificial intelligence. Rail Vision Ltd. (NASDAQ: RVSN, FSE: C80) is positioning itself squarely at the center of that…

FridayApr 10, 2026 11:15 am

Frontieras North America Inc. Unlocks Value in America’s Energy Future

Frontieras is developing breakthrough technologies that convert abundant solid hydrocarbons such as coal into cleaner fuels, hydrogen and industrial energy products. Central to this strategy is the company’s patented FASForm(TM) Solid Carbon Fractionation process. The company has not only developed its technology but is moving toward commercialization. Frontieras North America is emerging as a noteworthy innovator and attractive potential investment opportunity by addressing one of the most critical challenges facing modern technology: the rapidly growing demand for reliable, affordable electricity. As artificial intelligence (“AI”) and data-intensive computing expand, global electricity demand is projected to soar, with some analysts estimating AI-related…

FridayApr 10, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Accelerates Cancer Care Innovation with Liora Technologies Acquisition and Leadership Expansion

LIXT is advancing its lead compound LB-100 across different clinical programs aimed at difficult-to-treat cancers The company’s acquisition of Liora Technologies introduces a complementary therapy platform with recurring revenue potential These updates underscore LIXTE’s broader strategy: integrating drug development and med-tech innovation to redefine cancer treatment LIXTE Biotechnology (NASDAQ: LIXT) is executing a differentiated strategy in oncology, extending beyond traditional drug development into a more integrated and multi-dimensional approach to cancer care. With the company’s lead clinical candidate, LB-100, advancing through trials and the addition of Liora Technologies to its platform, they are positioning themselves at the nexus of pharmaceutical…

FridayApr 10, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Positions AI-Powered Collision Avoidance Tech as Solution to Rail Safety Mandates

The National Transportation Safety Board (“NTSB”) has intensified its focus on collision-prevention technologies following multiple rail incidents. Rail Vision’s proprietary sensor systems are designed to address key railway safety challenges by combining advanced imaging technologies with artificial intelligence and deep learning algorithms. The company’s technology is also designed to integrate with existing rail infrastructure, providing flexibility for operators seeking to upgrade safety capabilities without requiring extensive system overhauls. Rail-safety regulators are increasingly calling for advanced collision-avoidance systems as rail networks grow more complex, and Rail Vision’s (NASDAQ: RVSN, FSE: C80) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological…

ThursdayApr 09, 2026 10:30 am

Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The company recently strengthened its position through a strategic partnership with Liora Technologies and the expansion of clinical trials These developments highlight Lixte’s broader mission: To improve cancer outcomes through innovation, combination-based therapeutic strategies Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000